Drugs / Bendroflumethiazide

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) NATURETIN-5 1959-12-07 fda.gov

Trials 4 · a red edge is where a trial was stopped

19581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 41 trial
Phase 4 NCT04330300 Apr 2020 → Jul 2021 COVID-19, essential hypertension National University of Ireland, Galway, Ireland Suspended No outcome recorded
Phase not applicable3 trials
NCT00380289 Sep 2006 → ? essential hypertension University of Cambridge Unknown No outcome recorded
NCT00429897 Aug 2006 → Jul 2007 hypertensive disorder University of Cambridge Unknown No outcome recorded
NCT00518479 Sep 2003 → Apr 2004 hypertensive disorder, hypertensive heart disease University of Leeds Completed No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT05753059 Comparator Aug 2023 → Jun 2028 expected heart failure Yale University Recruiting No outcome recorded
Phase 1 NCT00648297 Comparator Aug 2006 Mylan Pharmaceuticals Inc Completed No outcome recorded
Phase 1 NCT00647660 Comparator Jul → Aug 2006 Mylan Pharmaceuticals Inc Completed No outcome recorded
Phase 41 trial
Phase 4 NCT02235402 Comparator Dec 1997 → Mar 2000 hypertensive disorder Boehringer Ingelheim Completed No outcome recorded

Evidence & citations 20 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Bendroflumethiazide “Hydrochlorothiazide, metolazone, chlorthalidone, chlorothiazide, bendroflumethiazide, indapamide” NCT04330300
5

NCT00647660

NCT05753059

NCT00518479

NCT00648297

NCT00429897

Known as Aprinox ChEMBL registry synonym — accepted as the source's own label CHEMBL1684
Known as Bendrofluazide “either Bendrofluazide 5-10mg daily, Atenolol 50-100mg daily or combination of Bendrofluazide 2.5-5mg and Atenolol 25-50mg daily” NCT00380289
1

NCT02235402

Known as Bendroflumethiazide component of corzide ChEMBL registry synonym — accepted as the source's own label CHEMBL1684
Known as Bendroflumetiazida ChEMBL registry synonym — accepted as the source's own label CHEMBL1684
Known as Berkozide ChEMBL registry synonym — accepted as the source's own label CHEMBL1684
Known as Centyl ChEMBL registry synonym — accepted as the source's own label CHEMBL1684
Known as Naturetin ChEMBL registry synonym — accepted as the source's own label CHEMBL1684
Known as Naturetin-10 ChEMBL registry synonym — accepted as the source's own label CHEMBL1684
Known as Naturetin-2.5 ChEMBL registry synonym — accepted as the source's own label CHEMBL1684
Known as Naturetin-5 ChEMBL registry synonym — accepted as the source's own label CHEMBL1684
Known as Neo-bendromax 2.5 ChEMBL registry synonym — accepted as the source's own label CHEMBL1684
Known as Neo-bendromax 5 ChEMBL registry synonym — accepted as the source's own label CHEMBL1684
Known as Neo-naclex ChEMBL registry synonym — accepted as the source's own label CHEMBL1684
Known as NSC-758229 ChEMBL registry synonym — accepted as the source's own label CHEMBL1684
Known as Urizide ChEMBL registry synonym — accepted as the source's own label CHEMBL1684
Action Inhibit “Thiazide-sensitive sodium-chloride cotransporter inhibitor” CHEMBL1684
Modality Small molecule CHEMBL1684
Route Oral “single, oral 80 mg/5 mg (1 x 80 mg/5 mg) dose administered under fasting conditions” NCT00647660
Target SLC12A3 “Thiazide-sensitive sodium-chloride cotransporter inhibitor” CHEMBL1684